<p><em>Natalie Holles，经验丰富的行业高管，拥有丰富的罕见疾病运营和商业化经验，被任命为首席执行官、总裁及董事会成员</em></p>
<p><em>患者筛查加速，推动第 3 阶段 CoMpass 试验入组接近完成</em></p>
<p>波士顿，2026 年 5 月 4 日（环球新闻通讯社）——Aura Biosciences, Inc.（纳斯达克：AURA），一家开发旨在保护器官功能的实体肿瘤精准疗法的临床阶段生物技术公司，今天宣布其董事会已任命 Natalie Holles 为首席执行官、总裁及董事会成员，自 2026 年 4 月 30 日起生效。Holles 女士接替了公司的创始人 Elisabet de los Pinos 博士，后者于同日辞去了首席执行官、总裁及董事会成员的职务。</p>
<p>公司还宣布，其针对早期脉络膜黑色素瘤的研究候选药物 belzupacap sarotalocan（bel-sar）的第 3 阶段 CoMpass 试验入组即将完成。截至今天，已有 86 名患者参与了该研究，超过 25 名患者已安排或确定在 2026 年 5 月前进行筛查。根据这一更新，公司重申预计将在 2026 年中期完成入组，并在 2027 年下半年获得 CoMpass 试验的初步数据。</p>
<p>“我很高兴能加入 Aura，带领公司进入下一个增长阶段，包括第 3 阶段试验的完成以及 bel-sar 的潜在注册和商业化发布，” Holles 女士表示。“我相信公司在为早期脉络膜黑色素瘤患者带来首个前线、保护视力的疗法方面，处于非常有利的位置，能够为我们的患者和股东创造重要的价值。我期待与这个才华横溢的团队合作，推动我们的工作，实现 bel-sar 的全部临床和商业潜力。”</p>
<p>“在这个重要时刻，我们非常高兴欢迎 Natalie 担任首席执行官，” Aura Biosciences 董事会主席 David Johnson 表示。“Natalie 在晚期开发、运营和罕见疾病商业化方面拥有丰富的经验，使她非常适合在我们接近完成第 3 阶段 CoMpass 试验的入组并准备潜在商业化时领导 Aura。代表董事会，我想感谢 Elisabet 在创立 Aura 和推动公司发展到这一关键阶段所做的领导和愿景。”</p>
<p>“能够从零开始创立和领导 Aura，并与如此卓越的团队并肩工作，真是一种荣幸，” de los Pinos 博士表示。“我对我们共同建立的成就感到深感自豪——推动肿瘤学创新、对患者和眼科肿瘤学领域的承诺，以及将 CoMpass 试验推进到这一重要阶段。随着公司进入下一个阶段，我期待看到它在 Natalie 的领导下继续成长和繁荣。”</p>
<p>Holles 女士拥有超过 25 年的高管领导经验，涵盖企业战略、业务发展、运营和多个治疗领域的商业化。在加入 Aura 之前，Holles 女士于 2021 年 8 月至 2025 年 12 月担任 Third Harmonic Bio 的首席执行官。在此之前，她曾担任 Audentes Therapeutics 的总裁兼首席执行官，该公司于 2020 年被 Astellas Pharma 收购。她于 2015 年加入 Audentes，担任高级副总裁兼首席运营官，是公司 GMP 病毒载体制造能力的重要架构师，随后于 2018 年晋升为总裁兼首席运营官，并于 2020 年晋升为首席执行官。在她的职业生涯早期，Holles 女士曾担任 Hyperion Therapeutics 的企业发展高级副总裁，该公司于 2015 年被 Horizon Pharma 收购，并担任 KAI Pharmaceuticals 的业务发展副总裁，该公司于 2012 年被 Amgen 收购。Holles 女士拥有斯坦福大学的人类生物学学士学位和科罗拉多大学博尔德分校的分子、细胞和发育生物学硕士学位。</p>
<p><strong>关于 Bel-sar 和 Aura 正在进行的早期脉络膜黑色素瘤第 3 阶段 CoMpass 试验：</strong> CoMpass 是早期脉络膜黑色素瘤的首个注册启用研究。这项全球随机第 3 阶段试验正在评估 bel-sar 与假控制的效果。截至今天，已有 86 名患者参与了该试验，超过 25 名患者已安排或确定在 2026 年 5 月前进行筛查。公司继续预计将在 2026 年中期完成入组，预计在 2027 年下半年获得 15 个月主要终点的初步数据。</p>
<p>Bel-sar 有潜力成为该领域首个前线保护视力的疗法。公司此前已获得美国食品药品监督管理局（FDA）和欧洲药品管理局的孤儿药资格，并获得 FDA 对早期脉络膜黑色素瘤治疗的快速通道资格。CoMpass 试验与 FDA 签署了特别方案评估协议。</p>
<p><strong>关于 Aura Biosciences</strong></p>
<p>Aura Biosciences 是一家临床阶段生物技术公司，专注于开发旨在保护器官功能的实体肿瘤精准疗法。我们的主要候选药物 bel-sar（AU-011）目前正在针对早期脉络膜黑色素瘤进行晚期开发，并在其他眼科肿瘤学适应症和膀胱癌中进行早期开发。Aura Biosciences 总部位于马萨诸塞州波士顿。我们的使命是成长为一家创新的全球肿瘤学公司，积极改变患者的生活。</p>
<p>欲了解更多信息，请访问 aurabiosciences.com。关注我们在 X 上的动态，@AuraBiosciences，并访问我们的 LinkedIn 页面。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1995 年《私人证券诉讼改革法案》及其他联邦证券法的定义的前瞻性声明。任何不是历史事实的陈述可能被视为前瞻性声明。诸如 “可能”、“将”、“能够”、“应该”、“期望”、“打算”、“计划”、“预期”、“相信”、“估计”、“预测”、“项目”、“寻求”、“努力”、“潜在”、“继续” 或这些词的否定形式或其他类似表达可以用来识别前瞻性声明。这些前瞻性声明包括关于 Aura 未来期望、计划和前景的明示或暗示的陈述，包括但不限于关于 bel-sar 在多种癌症治疗中的治疗潜力的陈述；关于 Aura 对其在多种肿瘤指征中进行的 bel-sar 临床试验的计划和期望的陈述，包括关于临床试验启动的相关内容；关于公司在早期脉络膜黑色素瘤的第 3 阶段 CoMpass 试验的时间安排和计划的陈述，包括入组预测和顶线数据的时间安排；关于 Aura 对 bel-sar 治疗后患者生活质量改善的期望以及对患者治疗模式变化的陈述；以及关于 Aura 对 bel-sar 预计患者群体和相关市场机会的期望的陈述。</p>
<p>本新闻稿中的前瞻性声明既不是承诺也不是保证，投资者不应对这些前瞻性声明过度依赖，因为它们涉及已知和未知的风险、不确定性及其他因素，其中许多超出了 Aura 的控制范围，可能导致实际结果与这些前瞻性声明所表达或暗示的结果存在重大差异，包括但不限于临床试验固有的不确定性以及来自正在进行的临床试验的数据可用性和时间安排；监管批准或政府机构审查的提交预期时间；Aura 的临床前和临床试验结果可能无法预测未来临床试验结果的风险；来自正在进行的临床试验的早期或中期数据可能无法预测已完成临床试验的最终数据的风险；即使 Aura 已与政府机构就这些试验的设计达成一致，政府机构可能仍会不同意 Aura 的临床试验设计的风险，例如与美国食品药品监督管理局的第 3 阶段特殊方案评估协议；Aura 是否会获得进行试验或市场产品的监管批准；Aura 的现金资源是否足以满足其可预见和不可预见的运营费用和资本支出要求；Aura 正在进行和计划的临床前活动；以及 Aura 启动、招募、进行或完成正在进行和计划的临床试验的能力。这些风险、不确定性和其他因素包括在 Aura 最近提交给美国证券交易委员会（SEC）的 10-K 表格年报中以及 Aura 随后向 SEC 提交的文件中描述的 “风险因素”，这些文件可在 SEC 网站 www.sec.gov 上获得。除法律要求外，Aura 不承担更新或修订本新闻稿中包含的任何前瞻性声明的意图或责任，除非有新信息、未来发展或其他情况。这些前瞻性声明基于 Aura 当前的期望，仅在本日期有效，并且不对任何此类前瞻性声明的准确性作出任何明示或暗示的陈述或保证。</p>
<p><strong>投资者和媒体关系联系人：</strong></p>
<p>Alex Dasalla</p>
<p>投资者关系和企业传播负责人</p>
<p>IR@aurabiosciences.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1qQTNOeU0zTlRnd016QTBJelV3TURFeU5ESTJNQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1qQTNOeU0zTlRnd016QTBJelV3TURFeU5ESTJNQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmY3MzgzZGMtNDIxZC00ZDBlLWE1ODktOGJkNDExNjhmYzBmLTUwMDEyNDI2MC0yMDI2LTA1LTA0LWVu/tiny/Aura-Biosciences-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmY3MzgzZGMtNDIxZC00ZDBlLWE1ODktOGJkNDExNjhmYzBmLTUwMDEyNDI2MC0yMDI2LTA1LTA0LWVu/tiny/Aura-Biosciences-Inc-.png"/></p>

AURA

<p>Aura Biosciences 已任命 Natalie Holles 为首席执行官兼总裁，接替创始人 Elisabet de los Pinos。该公司即将完成其针对早期脉络膜黑色素瘤的 belzupacap sarotalocan（bel-sar）的第三阶段 CoMpass 试验，目前已有 86 名患者入组，预计到 2026 年中期将有更多患者参与。Holles 拥有超过 25 年的生物技术行业经验，旨在引领公司度过这一关键阶段，目标是为患者提供首个保护视力的治疗方案。试验的顶线数据预计将在 2027 年下半年公布</p>

<p><em>Natalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointed Chief Executive Officer and President and member of the Board of Directors</em></p>
<div class="lb-trans"><p><em>Natalie Holles，经验丰富的行业高管，拥有丰富的罕见疾病运营和商业化经验，被任命为首席执行官、总裁及董事会成员</em></p>
</div><p><em>Acceleration in patient screening driving Phase 3 CoMpass trial enrollment to near completion</em></p>
<div class="lb-trans"><p><em>患者筛查加速，推动第 3 阶段 CoMpass 试验入组接近完成</em></p>
</div><p>BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that its Board of Directors has appointed Natalie Holles as Chief Executive Officer and President and member of the Board of Directors, effective April 30, 2026. Ms. Holles succeeds Elisabet de los Pinos, Ph.D., the Company’s founder, who stepped down from her roles as Chief Executive Officer and President and member of the Board of Directors on the same date.</p>
<div class="lb-trans"><p>波士顿，2026 年 5 月 4 日（环球新闻通讯社）——Aura Biosciences, Inc.（纳斯达克：AURA），一家开发旨在保护器官功能的实体肿瘤精准疗法的临床阶段生物技术公司，今天宣布其董事会已任命 Natalie Holles 为首席执行官、总裁及董事会成员，自 2026 年 4 月 30 日起生效。Holles 女士接替了公司的创始人 Elisabet de los Pinos 博士，后者于同日辞去了首席执行官、总裁及董事会成员的职务。</p>
</div><p>The Company also announced that its Phase 3 CoMpass trial with its investigational candidate belzupacap sarotalocan (bel-sar) for the treatment of early choroidal melanoma is nearing enrollment completion. As of today, 86 patients have been enrolled in the study, and more than 25 additional patients have been scheduled or identified for screening through May 2026. With this update, the Company reiterates its guidance to enrollment completion by mid-2026 and topline data from the CoMpass trial in the second half of 2027.</p>
<div class="lb-trans"><p>公司还宣布，其针对早期脉络膜黑色素瘤的研究候选药物 belzupacap sarotalocan（bel-sar）的第 3 阶段 CoMpass 试验入组即将完成。截至今天，已有 86 名患者参与了该研究，超过 25 名患者已安排或确定在 2026 年 5 月前进行筛查。根据这一更新，公司重申预计将在 2026 年中期完成入组，并在 2027 年下半年获得 CoMpass 试验的初步数据。</p>
</div><p>“I am thrilled to join Aura to lead the Company through this next phase of its growth, including Phase 3 trial completion and the potential registration and commercial launch of bel-sar,” said Ms. Holles. “With the potential to bring the first frontline, vision-preserving therapy to patients with early choroidal melanoma, I believe the Company is very well-positioned for meaningful value creation for our patients and shareholders. I look forward to working with this talented team to advance our work toward realizing the full clinical and commercial potential of bel-sar.”</p>
<div class="lb-trans"><p>“我很高兴能加入 Aura，带领公司进入下一个增长阶段，包括第 3 阶段试验的完成以及 bel-sar 的潜在注册和商业化发布，” Holles 女士表示。“我相信公司在为早期脉络膜黑色素瘤患者带来首个前线、保护视力的疗法方面，处于非常有利的位置，能够为我们的患者和股东创造重要的价值。我期待与这个才华横溢的团队合作，推动我们的工作，实现 bel-sar 的全部临床和商业潜力。”</p>
</div><p>“We are delighted to welcome Natalie as CEO at this important moment for Aura,” said David Johnson, Chairman of the Board of Directors of Aura Biosciences. “Natalie brings significant experience across late-stage development, operations, and rare disease commercialization, making her exceptionally well-suited to lead Aura as we near completion of enrollment in our Phase 3 CoMpass trial and prepare for potential commercialization. On behalf of the Board, I would like to thank Elisabet for her leadership and vision in founding Aura and advancing the Company to this critical point.”</p>
<div class="lb-trans"><p>“在这个重要时刻，我们非常高兴欢迎 Natalie 担任首席执行官，” Aura Biosciences 董事会主席 David Johnson 表示。“Natalie 在晚期开发、运营和罕见疾病商业化方面拥有丰富的经验，使她非常适合在我们接近完成第 3 阶段 CoMpass 试验的入组并准备潜在商业化时领导 Aura。代表董事会，我想感谢 Elisabet 在创立 Aura 和推动公司发展到这一关键阶段所做的领导和愿景。”</p>
</div><p>“It has truly been a privilege to found and lead Aura from the ground up and to work alongside such an extraordinary team,” said Dr. de los Pinos. “I am deeply proud of what we have built together—advancing innovation in oncology, our commitment to patients and the field of ocular oncology, and bringing the CoMpass trial to this important stage. As the Company moves into its next phase, I am excited to see it continue to grow and thrive under Natalie’s leadership.”</p>
<div class="lb-trans"><p>“能够从零开始创立和领导 Aura，并与如此卓越的团队并肩工作，真是一种荣幸，” de los Pinos 博士表示。“我对我们共同建立的成就感到深感自豪——推动肿瘤学创新、对患者和眼科肿瘤学领域的承诺，以及将 CoMpass 试验推进到这一重要阶段。随着公司进入下一个阶段，我期待看到它在 Natalie 的领导下继续成长和繁荣。”</p>
</div><p>Ms. Holles has more than 25 years of executive leadership experience spanning corporate strategy, business development, operations and commercialization across multiple therapeutic areas. Prior to joining Aura, Ms. Holles served as Chief Executive Officer of Third Harmonic Bio from August 2021 through December 2025. Before that, she was President and Chief Executive Officer of Audentes Therapeutics, which was acquired by Astellas Pharma in 2020. She joined Audentes as Senior Vice President and Chief Operating Officer in 2015, was an instrumental architect of the Company’s GMP viral vector manufacturing capabilities and was subsequently promoted to President and Chief Operating Officer in 2018, and then to Chief Executive Officer in 2020. Earlier in her career, Ms. Holles served as Senior Vice President of Corporate Development at Hyperion Therapeutics, which was acquired by Horizon Pharma in 2015, and as Vice President of Business Development at KAI Pharmaceuticals, which was acquired by Amgen in 2012. Ms. Holles holds an A.B. in Human Biology from Stanford University and an M.A. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder.</p>
<div class="lb-trans"><p>Holles 女士拥有超过 25 年的高管领导经验，涵盖企业战略、业务发展、运营和多个治疗领域的商业化。在加入 Aura 之前，Holles 女士于 2021 年 8 月至 2025 年 12 月担任 Third Harmonic Bio 的首席执行官。在此之前，她曾担任 Audentes Therapeutics 的总裁兼首席执行官，该公司于 2020 年被 Astellas Pharma 收购。她于 2015 年加入 Audentes，担任高级副总裁兼首席运营官，是公司 GMP 病毒载体制造能力的重要架构师，随后于 2018 年晋升为总裁兼首席运营官，并于 2020 年晋升为首席执行官。在她的职业生涯早期，Holles 女士曾担任 Hyperion Therapeutics 的企业发展高级副总裁，该公司于 2015 年被 Horizon Pharma 收购，并担任 KAI Pharmaceuticals 的业务发展副总裁，该公司于 2012 年被 Amgen 收购。Holles 女士拥有斯坦福大学的人类生物学学士学位和科罗拉多大学博尔德分校的分子、细胞和发育生物学硕士学位。</p>
</div><p><strong>About Bel- sar and Aura’s Ongoing Phase 3 CoMpass Trial in Early Choroidal Melanoma:</strong> CoMpass is the first registration-enabling study in early choroidal melanoma. This global, randomized Phase 3 trial is evaluating bel-sar versus a sham control. As of today, 86 patients have been enrolled in the trial and over 25 patients are scheduled or identified for screening through May 2026. The Company continues to expect to complete enrollment by mid-2026, with topline data for the 15-month primary endpoint anticipated in the second half of 2027.</p>
<div class="lb-trans"><p><strong>关于 Bel-sar 和 Aura 正在进行的早期脉络膜黑色素瘤第 3 阶段 CoMpass 试验：</strong> CoMpass 是早期脉络膜黑色素瘤的首个注册启用研究。这项全球随机第 3 阶段试验正在评估 bel-sar 与假控制的效果。截至今天，已有 86 名患者参与了该试验，超过 25 名患者已安排或确定在 2026 年 5 月前进行筛查。公司继续预计将在 2026 年中期完成入组，预计在 2027 年下半年获得 15 个月主要终点的初步数据。</p>
</div><p>Bel-sar has the potential to become the first frontline vision-preserving therapy in this setting. The Company previously received Orphan Drug Designation from the United States Food and Drug Administration (FDA) and the European Medicines Agency and Fast Track designation from the FDA for the treatment of early choroidal melanoma. The CoMpass trial is under a Special Protocol Assessment agreement with the FDA.</p>
<div class="lb-trans"><p>Bel-sar 有潜力成为该领域首个前线保护视力的疗法。公司此前已获得美国食品药品监督管理局（FDA）和欧洲药品管理局的孤儿药资格，并获得 FDA 对早期脉络膜黑色素瘤治疗的快速通道资格。CoMpass 试验与 FDA 签署了特别方案评估协议。</p>
</div><p><strong>About Aura Biosciences</strong></p>
<div class="lb-trans"><p><strong>关于 Aura Biosciences</strong></p>
</div><p>Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.</p>
<div class="lb-trans"><p>Aura Biosciences 是一家临床阶段生物技术公司，专注于开发旨在保护器官功能的实体肿瘤精准疗法。我们的主要候选药物 bel-sar（AU-011）目前正在针对早期脉络膜黑色素瘤进行晚期开发，并在其他眼科肿瘤学适应症和膀胱癌中进行早期开发。Aura Biosciences 总部位于马萨诸塞州波士顿。我们的使命是成长为一家创新的全球肿瘤学公司，积极改变患者的生活。</p>
</div><p>For more information, visit aurabiosciences.com. Follow us on X, @AuraBiosciences, and visit us on LinkedIn.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 aurabiosciences.com。关注我们在 X 上的动态，@AuraBiosciences，并访问我们的 LinkedIn 页面。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “may,” “will,” “could,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include express or implied statements regarding Aura’s future expectations, plans and prospects, including, without limitation, statements regarding the therapeutic potential of bel-sar for the treatment of multiple cancers; statements regarding Aura’s plans and expectations for its ongoing and future clinical trials of bel-sar in multiple oncology indications, including with respect to clinical trial initiations; statements regarding the timing and plans for the Company’s Phase 3 CoMpass trial in early choroidal melanoma, including enrollment projections and the timing of topline data; statements regarding Aura’s expectations for an improved quality of life of patients after treatment with bel-sar and changes to the treatment paradigm for patients; and statements regarding Aura’s expectations for the estimated patient populations and related market opportunities for bel-sar.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年《私人证券诉讼改革法案》及其他联邦证券法的定义的前瞻性声明。任何不是历史事实的陈述可能被视为前瞻性声明。诸如 “可能”、“将”、“能够”、“应该”、“期望”、“打算”、“计划”、“预期”、“相信”、“估计”、“预测”、“项目”、“寻求”、“努力”、“潜在”、“继续” 或这些词的否定形式或其他类似表达可以用来识别前瞻性声明。这些前瞻性声明包括关于 Aura 未来期望、计划和前景的明示或暗示的陈述，包括但不限于关于 bel-sar 在多种癌症治疗中的治疗潜力的陈述；关于 Aura 对其在多种肿瘤指征中进行的 bel-sar 临床试验的计划和期望的陈述，包括关于临床试验启动的相关内容；关于公司在早期脉络膜黑色素瘤的第 3 阶段 CoMpass 试验的时间安排和计划的陈述，包括入组预测和顶线数据的时间安排；关于 Aura 对 bel-sar 治疗后患者生活质量改善的期望以及对患者治疗模式变化的陈述；以及关于 Aura 对 bel-sar 预计患者群体和相关市场机会的期望的陈述。</p>
</div><p>The forward-looking statements in this press release are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Aura’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, without limitation, uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials; the expected timing for submissions for regulatory approval or review by governmental authorities; the risk that the results of Aura’s preclinical and clinical trials may not be predictive of future results in connection with future clinical trials; the risk that early or interim data from ongoing clinical trials may not be predictive of final data from completed clinical trials; the risk that governmental authorities may disagree with Aura’s clinical trial designs, even where Aura has obtained agreement with governmental authorities on the design of such trials, such as the Phase 3 special protocol assessment agreement with the U.S. Food and Drug Administration; whether Aura will receive regulatory approvals to conduct trials or to market products; whether Aura’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; Aura’s ongoing and planned preclinical activities; and Aura’s ability to initiate, enroll, conduct or complete ongoing and planned clinical trials. These risks, uncertainties and other factors include those risks and uncertainties described under the heading “Risk Factors” in Aura’s most recent Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) and in subsequent filings made by Aura with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Aura disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Aura’s current expectations and speak only as of the date hereof and no representations or warranties (express or implied) are made about the accuracy of any such forward-looking statements.</p>
<div class="lb-trans"><p>本新闻稿中的前瞻性声明既不是承诺也不是保证，投资者不应对这些前瞻性声明过度依赖，因为它们涉及已知和未知的风险、不确定性及其他因素，其中许多超出了 Aura 的控制范围，可能导致实际结果与这些前瞻性声明所表达或暗示的结果存在重大差异，包括但不限于临床试验固有的不确定性以及来自正在进行的临床试验的数据可用性和时间安排；监管批准或政府机构审查的提交预期时间；Aura 的临床前和临床试验结果可能无法预测未来临床试验结果的风险；来自正在进行的临床试验的早期或中期数据可能无法预测已完成临床试验的最终数据的风险；即使 Aura 已与政府机构就这些试验的设计达成一致，政府机构可能仍会不同意 Aura 的临床试验设计的风险，例如与美国食品药品监督管理局的第 3 阶段特殊方案评估协议；Aura 是否会获得进行试验或市场产品的监管批准；Aura 的现金资源是否足以满足其可预见和不可预见的运营费用和资本支出要求；Aura 正在进行和计划的临床前活动；以及 Aura 启动、招募、进行或完成正在进行和计划的临床试验的能力。这些风险、不确定性和其他因素包括在 Aura 最近提交给美国证券交易委员会（SEC）的 10-K 表格年报中以及 Aura 随后向 SEC 提交的文件中描述的 “风险因素”，这些文件可在 SEC 网站 www.sec.gov 上获得。除法律要求外，Aura 不承担更新或修订本新闻稿中包含的任何前瞻性声明的意图或责任，除非有新信息、未来发展或其他情况。这些前瞻性声明基于 Aura 当前的期望，仅在本日期有效，并且不对任何此类前瞻性声明的准确性作出任何明示或暗示的陈述或保证。</p>
</div><p><strong>Investor and Media Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者和媒体关系联系人：</strong></p>
</div><p>Alex Dasalla</p>
<div class="lb-trans"><p>Alex Dasalla</p>
</div><p>Head of Investor Relations and Corporate Communications</p>
<div class="lb-trans"><p>投资者关系和企业传播负责人</p>
</div><p>IR@aurabiosciences.com</p>
<div class="lb-trans"><p>IR@aurabiosciences.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1qQTNOeU0zTlRnd016QTBJelV3TURFeU5ESTJNQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcxMjA3NyM3NTgwMzA0IzUwMDEyNDI2MA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmY3MzgzZGMtNDIxZC00ZDBlLWE1ODktOGJkNDExNjhmYzBmLTUwMDEyNDI2MC0yMDI2LTA1LTA0LWVu/tiny/Aura-Biosciences-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NmY3MzgzZGMtNDIxZC00ZDBlLWE1ODktOGJkNDExNjhmYzBmLTUwMDEyNDI2MC0yMDI2LTA1LTA0LWVu/tiny/Aura-Biosciences-Inc-.png"/></p>

Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion  | AURA Stock News

StockTitan

Aura Biosciences

Aura Biosciences 宣布 CEO 过渡，公司推进 3 期 CoMpass 试验以完成招募 | AURA 股票新闻